Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation

Clinical Transplantation

Volumn 26, Issue 3, 2012, Pages 447-453

  Ganguly, Siddhartha ^a   Divine, Clint L ^a   Aljitawi, Omar S ^a   Abhyankar, Sunil ^a   Mcguirk, Joseph P ^a   Graves, Leland ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Allogeneic stem cell transplantation; Osteoporosis; Zoledronic acid

Indexed keywords

ACICLOVIR; AMINO TERMINAL TELOPEPTIDE; BUSULFAN; CYCLOPHOSPHAMIDE; FLUCONAZOLE; FLUDARABINE; LEVOFLOXACIN; METHOTREXATE; OSTEOCALCIN; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; ZOLEDRONIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEASIBILITY STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPOCALCEMIA; INFECTION PREVENTION; JAW OSTEONECROSIS; MALE; OSTEOLYSIS; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; URINE;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; OSTEOPOROSIS; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84862250865     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01527.x     Document Type: Article

References (21)

1. Schimmer AD, Minden MD, Keating A. Osteoporosis after blood and marrow transplantation: clinical aspects. Biol Blood Marrow Transplant 2000: 6: 175.
2. Kelly PJ, Atkinson K, Ward RL et al. Reduced bone mineral density in men and women with allogeneic bone marrow transplantation. Transplantation 1990: 50: 881.
3. Schulte CM, Beelen DW. Bone loss following hematopoietic stem cell transplantation: a long-term follow up. Blood 2004: 103: 3635.
4. Ebeling PR, Thomas DM, Erbas B et al. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res 1999: 14: 342.
5. Stern JM, Chestnut CH III, Bruemmer B et al. Bone Density Loss during treatment of chronic GVHD. Bone Marrow Transplant 1996: 17: 395.
6. Orcel P, Denne MA, De Vernejul MC. Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of monocyte-macrophage lineage. Endocrinology 1991: 128: 1638.
7. Petropoulou AD, Porcher R, Herr AL et al. Prospective assessment of bone turnover and clinical bone diseases after allogeneic hematopoietic stem-cell transplantation. Transplantation 2010: 89: 1354.
8. Massenkeil G, Fiene C, Rosen O et al. Loss of bone mass and vitamin D deficiency after hematopoietic stem cell transplantation: standard prophylactic measures fail to prevent osteoporosis. Leukemia 2001: 15: 1701.
9. Kim SH, Lim SK, Hahn JS. Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy. Am J Med 2004: 116: 524.
10. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042. Erratum in: J Clin Oncol 2004; 22: 1351.
11. Terpos E, Sezer O, Croucher PI et al. European Myeloma Network. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009: 20: 1303.
12. Tauchmanova L, Ricci P, Serio B et al. Short-term Zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2010: 90: 627.
13. D'Souza AB, Grigg AP, Szer J et al. Zoledronic acid prevents bone loss after allogeneic haematopoietic stem cell transplantation. Internal Medicine Journal 2006: 36: 600.
14. Chae YS, Kim JG, Moon JH et al. Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients. Bone Marrow Transplant 2009: 44: 35.
15. Lenchik L, Kiebzak GM, Blunt BA. What is the role of serial bone mineral density measurements in patient management? J Clin Densitom 2002: 5: S29.
16. Garnero P, Gineyts E, Arbault P et al. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995: 10: 641.
17. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 2008: 12: 157.
18. Schulte C, Beelen DW, Schaefer UW et al. Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study. Osteoporos Int 2000: 11: 344.
19. Eyre DR. Bone biomarkers as tools in osteoporosis management. Spine 1997: 22(24 Suppl): 17S.
20. Rosen CJ, Chesnut CH III, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997: 82: 1904.
21. McClune BL, Polgreen LE, Burmeister LA et al. Screening, prevention, and management of osteoporosis and bone loss in adult and pediatric hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2011: 46: 1.